Swiss drug maker Roche Holding AG has announced that it will no longer manufacture its acne drug Accutane in the US. The company said that making Accutane was no longer viable in face of competition from generic versions of the drug.
Roche's patent for Accutane expired in 2002 and since then generic versions have dominated the market. Furthermore Roche is facing 5,000 plus lawsuits over accutane's side effects that include depression and inflammatory bowel disease.
"Roche stands behind the safety of Accutane and the rigorous risk-management program Roche developed over decades of cooperation with the FDA," said a statement issued by Shelley Rosenstock, a spokeswoman for Roche US.